Stockscreener 앱 받기
1.09
6.84%
-0.08
시간 외 거래:
1.14
0.05
+4.59%
전일 마감가:
$1.17
열려 있는:
$1.15
하루 거래량:
1.53M
Relative Volume:
1.40
시가총액:
$77.07M
수익:
-
순이익/손실:
$-95.71M
주가수익비율:
-0.4558
EPS:
-2.3915
순현금흐름:
$-87.27M
1주 성능:
-22.70%
1개월 성능:
-17.42%
6개월 성능:
-44.10%
1년 성능:
-60.07%
1일 변동 폭
$1.09
$1.155
1주일 범위
$1.09
$1.445
52주 변동 폭
$0.8719
$3.08
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.09 | 82.72M | 0 | -95.71M | -87.27M | -2.3915 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-08-28 | 개시 | Jefferies | Buy |
| 2025-06-03 | 재개 | Piper Sandler | Overweight |
| 2024-10-09 | 개시 | Edward Jones | Buy |
| 2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | 업그레이드 | Truist | Hold → Buy |
| 2024-08-29 | 개시 | CapitalOne | Overweight |
| 2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
| 2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 개시 | Truist | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-12 | 개시 | Barclays | Overweight |
| 2023-03-29 | 재확인 | Oppenheimer | Outperform |
| 2023-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2023-02-24 | 개시 | Citigroup | Buy |
| 2022-06-02 | 재개 | H.C. Wainwright | Buy |
| 2022-01-12 | 개시 | H.C. Wainwright | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Jefferies | Buy |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
Heights Capital Management Inc. Reduces Stock Holdings in Biomea Fusion, Inc. $BMEA - MarketBeat
BMEA SEC FilingsBiomea Fusion, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Why Is Biomea Fusion (BMEA) Stock Down 63% Today? - TradingView
Biomea Fusion, Inc. (BMEA) Presents at 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026Slideshow (NASDAQ:BMEA) 2026-03-16 - Seeking Alpha
Biomea Fusion Presents Positive Phase II COVALENT-111 Data in Type 2 Diabetes - National Today
Juan Pablo Frias presents diabetes research for Biomea Fusion at ATTD 2026 - Traders Union
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib - Benzinga
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - The Manila Times
Biomea Fusion Reports Positive 52-Week Results for Icovamenib in Type 2 Diabetes at ATTD 2026 Conference - Quiver Quantitative
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 - GlobeNewswire
D. Boral Capital Maintains Biomea Fusion (BMEA) Buy Recommendation - MSN
Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027 - MarketBeat
Biomea Fusion, Inc. (BMEA) Presents at The Citizens Life Sciences Conference 2026Slideshow - Seeking Alpha
Aug Fed Impact: Can Biomea Fusion Inc sustain its profitabilityMarket Movers & Risk Managed Investment Entry Signals - baoquankhu1.vn
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biomea Fusion to present icovamenib clinical data at ATTD 2006 - Traders Union
Biomea Fusion : Presentation Citizens Life Sciences Conference March 2026 - marketscreener.com
Icovamenib advances drive optimism for diabetes cure, Biomea Fusion asserts - Traders Union
Biomea Fusion (BMEA) Price Target Decreased by 10.64% to 7.14 - MSN
BMEA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Biomea Fusion, Inc. (BMEA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
Aug Spikes: Can Biomea Fusion Inc ride the EV waveWeekly Profit Analysis & Real-Time Stock Entry Alerts - baoquankhu1.vn
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf. - MarketBeat
BMEA: Icovamenib and BMF-650 advance in trials, targeting unmet needs in diabetes and weight loss - TradingView
Biomea Fusion : 1ST QUARTER 2026 Corporate Presentation OPCO - marketscreener.com
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline - TipRanks
Biomea Fusion posts updated investor presentation, confirms Phase II readouts and Phase I obesity data timing - TradingView
Biomea Fusion (NASDAQ: BMEA) details icovamenib and BMF-650 trial milestones - Stock Titan
Does Biomea Fusion Inc. stock trade at a discount to peersOptions Play & Momentum Based Trading Signals - mfd.ru
Biomea Fusion to Participate at Upcoming Investor Conferences - Investing News Network
Biomea Fusion advances metabolic disease science with visionary approach - Traders Union
7.85M Biomea Fusion (BMEA) shares reported in 9.9% ownership filing - Stock Titan
BMEA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can Biomea Fusion Inc. sustain its profitabilityMarket Risk Analysis & Smart Money Movement Tracker - mfd.ru
How Biomea Fusion Inc. stock reacts to job market dataWeekly Earnings Recap & Proven Capital Preservation Methods - mfd.ru
Can Biomea Fusion Inc. ride the EV waveJuly 2025 Trade Ideas & Reliable Trade Execution Plans - mfd.ru
BMEA Should I Buy - Intellectia AI
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Biomea Fusion Inc. stock appeals to analysts2025 Geopolitical Influence & Smart Swing Trading Techniques - mfd.ru
BMEA PE Ratio & Valuation, Is BMEA Overvalued - Intellectia AI
Why Biomea Fusion Inc. stock is recommended by analystsJuly 2025 WrapUp & Consistent Profit Trade Alerts - mfd.ru
Biomea Fusion (NASDAQ:BMEA) Shares Down 3%What's Next? - MarketBeat
Is Biomea Fusion Inc. stock a falling knife or bargain buy2025 Big Picture & Proven Capital Preservation Methods - mfd.ru
Biomea Fusion signals risk of beta cell overwork in diabetes - Traders Union
Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know - MSN
Does Biomea Fusion Inc stock benefit from AI growth2025 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
Market Catalysts: Is Biomea Fusion Inc part of any major indexJuly 2025 Rallies & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38% - Yahoo Finance
Levels Update: Does Biomea Fusion Inc offer margin of safetyQuarterly Performance Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):